VivoSeq
Other

AML

1

Pipeline Programs↗

14

Active Trials↗

15

Companies Involved↗

AML is an early-stage landscape with 1 program across 15 companies. The most active players are Pfizer, TScan Therapeutics, Inc., Teva.

Intelligence

Pipeline Metrics

Competitive Density

33/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

83/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pfizer logo

Pfizer

1 program

Phase 1T

TScan Therapeutics, Inc.

1 program

Phase 1Teva logo

Teva

0 programs

PreclinicalAstraZeneca logo

AstraZeneca

0 programs

PreclinicalMylan Pharmaceuticals Inc logo

Mylan Pharmaceuticals Inc

0 programs

PreclinicalA

Actinium Pharmaceuticals

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 11

Soc

Pfizer

Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

63

clinical trials

Completed33 · 52%
Recruiting10 · 16%
Unknown status9 · 14%
Withdrawn4 · 6%
Terminated3 · 5%
Active, not recruiting2 · 3%
Other2 · 3%

Clinical Trials

Trial Activity

63 trials

Azacitidine in Combination With Low Dose Intensity Venetoclax in Patients With AML Incl. Explorative AML Profiling
Recruiting·—·Phase 2·NCT05431257·117 enrolled
Intermediate-dose HAD Regimen for CEBPA Double-mutated AML
Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·N/A·NCT06529250·148 enrolled
Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation
Recruiting·VVirginia Commonwealth University·Phase 1·NCT07130695·15 enrolled
VAC Regimen for AML Patients Who Failed to Response to VA Regimen
Recruiting·TThe First Affiliated Hospital of Soochow University·Phase 2·NCT06220162·32 enrolled
Cladribine Venetoclax in Monocytic AML
Recruiting·UUniversity of Colorado, Denver·Phase 2·NCT06232655·20 enrolled
De-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding Patients
Recruiting·IInstitut Paoli-Calmettes·Phase 2·NCT06557421·50 enrolled
Novel Approaches to Target MECOM/EVI1 in AML
Recruiting·GGruppo Italiano Malattie EMatologiche dell'Adulto·N/A·NCT05839392·24 enrolled
A Phase I Study of Euthare-155008(ETH-155008) in AML and NHL Patients
Recruiting·SShengke Pharmaceuticals (Jiangsu) Limited, China·Phase 1·NCT05758610·60 enrolled
Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML
Recruiting·TThe First Affiliated Hospital of Soochow University·Phase 2/3·NCT05805098·60 enrolled
A Phase 1/3 Study Evaluating the Efficacy and Safety of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation (ALLOHA-2)
Recruiting·TTScan Therapeutics, Inc.·Phase 1·NCT05473910·310 enrolled
An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 Substrates
Active, not recruiting·Sanofi logoSanofi·Phase 1·NCT06686628·23 enrolled
ALLG AMLM26 INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML): A Multi-arm, Precision-based, Recursive, Platform Trial
Active, not recruiting·MM.D. Anderson Cancer Center·Preclinical·NCT06664879·3 enrolled
Role of Amlodipine in Reduction of CIN
Not yet recruiting·MMinia University·Phase 1·NCT07291375·40 enrolled
Daunorubicin + Cytarabine + Venetoclax in de Novo AML
Enrolling by invitation·—·N/A·NCT06697327·94 enrolled
LY3214996 in Patients With AML Who Are Not Candidates for Standard Therapy
Completed·—·Phase 1·NCT04081259·17 enrolled
Page 1 of 5

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)